PL448316A1 - Preparat biologiczny zawierający limfocyty pozbawione adhezyjnego receptora oddziałującego z białkami G F5 o działaniu przeciwnowotworowym - Google Patents

Preparat biologiczny zawierający limfocyty pozbawione adhezyjnego receptora oddziałującego z białkami G F5 o działaniu przeciwnowotworowym

Info

Publication number
PL448316A1
PL448316A1 PL448316A PL44831624A PL448316A1 PL 448316 A1 PL448316 A1 PL 448316A1 PL 448316 A PL448316 A PL 448316A PL 44831624 A PL44831624 A PL 44831624A PL 448316 A1 PL448316 A1 PL 448316A1
Authority
PL
Poland
Prior art keywords
preparation containing
proteins
biological preparation
anticancer activity
adhesion receptor
Prior art date
Application number
PL448316A
Other languages
English (en)
Inventor
Damian Jacenik
Jakub FICHNA
Original Assignee
Uniwersytet Łódzki
Uniwersytet Medyczny w Łodzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Łódzki, Uniwersytet Medyczny w Łodzi filed Critical Uniwersytet Łódzki
Priority to PL448316A priority Critical patent/PL448316A1/pl
Priority to PCT/IB2025/053893 priority patent/WO2025224558A1/en
Publication of PL448316A1 publication Critical patent/PL448316A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/52—Intestine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest preparat biologiczny zawierający od 0,5 do 1x106 limfocytów T subpopulacji CD4+ pozbawionych ADGRF5 do zastosowania jako lek oraz jego zastosowanie w chorobach nowotworowych przewodu pokarmowego, zwłaszcza guzów litych.
PL448316A 2024-04-24 2024-04-24 Preparat biologiczny zawierający limfocyty pozbawione adhezyjnego receptora oddziałującego z białkami G F5 o działaniu przeciwnowotworowym PL448316A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL448316A PL448316A1 (pl) 2024-04-24 2024-04-24 Preparat biologiczny zawierający limfocyty pozbawione adhezyjnego receptora oddziałującego z białkami G F5 o działaniu przeciwnowotworowym
PCT/IB2025/053893 WO2025224558A1 (en) 2024-04-24 2025-04-14 Biological preparation containing lymphocytes without adhesion g protein-coupled receptor f5 with anti-tumor activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL448316A PL448316A1 (pl) 2024-04-24 2024-04-24 Preparat biologiczny zawierający limfocyty pozbawione adhezyjnego receptora oddziałującego z białkami G F5 o działaniu przeciwnowotworowym

Publications (1)

Publication Number Publication Date
PL448316A1 true PL448316A1 (pl) 2025-10-27

Family

ID=95519177

Family Applications (1)

Application Number Title Priority Date Filing Date
PL448316A PL448316A1 (pl) 2024-04-24 2024-04-24 Preparat biologiczny zawierający limfocyty pozbawione adhezyjnego receptora oddziałującego z białkami G F5 o działaniu przeciwnowotworowym

Country Status (2)

Country Link
PL (1) PL448316A1 (pl)
WO (1) WO2025224558A1 (pl)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121454A1 (en) * 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
CN114058589A (zh) * 2020-07-30 2022-02-18 华东师范大学 具有嵌合抗原受体修饰的免疫细胞、制备方法和药物
CN114958770A (zh) * 2022-06-16 2022-08-30 华东师范大学 嵌合抗原受体nk细胞及其制备方法和细胞药物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121454A1 (en) * 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
CN114058589A (zh) * 2020-07-30 2022-02-18 华东师范大学 具有嵌合抗原受体修饰的免疫细胞、制备方法和药物
CN114958770A (zh) * 2022-06-16 2022-08-30 华东师范大学 嵌合抗原受体nk细胞及其制备方法和细胞药物及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAI LIU ET AL.: "World J Gastrointest Surg. 2024 March 27; 16(3): 700-709", ANALYSIS OF THE IMPACT OF IMMUNOTHERAPY EFFICACY AND SAFETY IN PATIENTS WITH GASTRIC CANCER AND LIVER METASTASIS. *
KANG, H. ET AL.: "Cells; 2022; 11(23): 3876", THE EXPRESSION PATTERN OF ADHESION G PROTEIN-COUPLED RECEPTOR F5 IS RELATED TO CELL ADHESION AND METASTATIC PATHWAYS IN COLORECTAL CANCER-COMPREHENSIVE STUDY BASED ON IN SILICO ANALYSIS. *

Also Published As

Publication number Publication date
WO2025224558A1 (en) 2025-10-30

Similar Documents

Publication Publication Date Title
TWI641371B (zh) 免疫相關及發炎疾病之治療
Zhang et al. Vitamin D deficiency in association with endothelial dysfunction: Implications for patients withCOVID-19
Levescot et al. BCR-ABL–induced deregulation of the IL-33/ST2 pathway in CD34 (+) progenitors from chronic myeloid leukemia patients
Albertini et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
Vallet et al. Myeloma bone disease: update on pathogenesis and novel treatment strategies
Iachininoto et al. Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2, 3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells
EP3184117A1 (en) Methods and compositions for the treatment of cancer
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
US20250026714A1 (en) METHODS OF USING RARy AGONISTS FOR CANCER TREATMENT
Oh et al. Direct regulation of IL-2 by curcumin
Leung et al. Novel anticancer strategy by targeting the gut microbial neurotransmitter signaling to overcome immunotherapy resistance
Li et al. A novel allogeneic rituximab-conjugated gamma delta T cell therapy for the treatment of relapsed/refractory B-cell lymphoma
Reddy Stem cells: Current status and therapeutic implications
Ma et al. Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo
Pacini et al. Gc protein-derived macrophage-activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay
Way et al. Physiological pathways mediating between psychological stress and health.
US20180036424A1 (en) Immune system enhancing immunotherapy for the treatment of cancer
Johnstone et al. Promises and challenges of immunogenic chemotherapy in multiple myeloma
Gao et al. Sperm protein 17 expression by murine epithelial ovarian cancer cells and its impact on tumor progression
Hulíková et al. Antitumor activity of N-acetyl-D-glucosamine-substituted glycoconjugates and combined therapy with keyhole limpet hemocyanin in B16F10 mouse melanoma model
US20240424022A1 (en) In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
He et al. HDAC inhibitor LBH589 suppresses the proliferation but enhances the antileukemic effect of human γδT cells
Tang et al. Pentapeptide AYP from Isochrysis zhanjiangensis exhibits antiangiogenic activity in HT1080 cells and HUVECs by suppressing migration and invasion in vitro
SE0000597D0 (sv) Novel antibody